xRead - September 2022

Wise et al.

Page 424

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion open, no control group

ILIT may induce allergen-specific plasmablasts. Confirms an effect on provocation of mast cells in skin and nasal mucosa during the ensuing winter.

Combined symptom and medication score, RQLQ, number of IgE+ and

IgE− plasmablasts specific for grass

1 Three injections of 1000 SQ-U of allergen, dose interval 23-36 days

Grass-pollen-allergy-induced AR (n = 7):

Study Year LOE

2016 4 Pilot study,

Schmid et al. 1722

AR = allergic rhinitis; Ig = immunoglobulin; ILIT = intralymphatic immunotherapy; LOE = level of evidence; MAT = modular antigen transporter; QOL = quality of life; RCT = randomized controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SPT = skin-prick test; SQ-U = standardized quality units; VAS = visual analogue scale.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.